Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease

The FDA clinical hold covers two Phase 3 studies for nexiguran ziclumeran, or nex-z, an experimental gene-editing therapy for transthyretin amyloidosis. Nex-z uses the CRISPR gene-editing technology to inactivate the gene that codes for the protein driving this rare disease. The post Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a…

Read More

Creating Exceptional Patient Experiences Starts with Identity Intelligence

We must work together across the care continuum to establish both local and network-trusted identity data management capabilities that can unify patient data across fragmented data silos at both the database layer and the front-end digital and physical access layer.   The post Creating Exceptional Patient Experiences Starts with Identity Intelligence appeared first on MedCity News.

Read More

Innovation Fatigue is Rampant: What’s the Rx to Fix It?

It’s not the flashiest technologies or rapid-speed AI breakthroughs that can do it. It’s the technologies laser-focused on the unglamorous but all-consuming coordination problems that suck up medical staff’s time, stress them out, and compromise patient care.  The post Innovation Fatigue is Rampant: What’s the Rx to Fix It? appeared first on MedCity News.

Read More